SenoSENSE Medical Systems , a medical device company, has completed enrolment in a 100-patient study of its Electrical Breast Densitometer system to measure breast density.
The Electrical Breast Densitometer is designed to evaluate the breast density, the most significant non-genetic risk factor for breast cancer, using a proprietary Densitrode sensor and electronics.
Mount Sinai Hospital Marvelle Koffler Breast Centre and Princess Margaret Hospital Gattuso Rapid Diagnosis Clinic affiliate breast radiologist Dr Karina Bukhanov said breast density is one of the major factors in developing breast cancer.
"Our ability to identify these women will allow us to screen this population more effectively and also permit these women to implement risk prevention techniques," Bukhanov said.
According to the company, the density test, which does not take more than a minute, will be painless and does not emit any radiation.
The initial study, which enrolled 20 patients, was conducted under the direction of principal investigator Dr Bukhanov at Timmins at District Hospital.
SenoSENSE Medical Systems president and chief executive officer Joel Ironstone said the completion of the initial human study represents an important milestone.
"We believe that the Electrical Breast Densitometer offers great promise to identify younger women who are at increased risk of breast cancer and enable proactive intervention to reduce their risk and initiate earlier surveillance in order to identify cancer at an earlier and more treatable stage," Ironstone said.